Yüklüyor......
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
More than simply a promising management option, PARP inhibitors can be regarded as a milestone in the development of personalised treatment of recurrent ovarian carcinoma. Their mechanism of action, known as “synthetic lethality”, is dependent on functional differences of the DNA repair mechanisms o...
Kaydedildi:
| Yayımlandı: | Geburtshilfe Frauenheilkd |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Georg Thieme Verlag KG
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4771499/ https://ncbi.nlm.nih.gov/pubmed/26941449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0035-1558185 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|